Similar to the previous clinical trials and real‐world studies, we also observed that alectinib was superior to crizotinib in prolonging survival of ALK‐positive and TKI‐naive NSCLC, and still had satisfactory effects in patients who progressed to crizotinib treatment. This evidence concerns the gene ALK and non-small cell lung carcinoma.